Pulmonary Rehabilitation for Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether pulmonary rehabilitation can help individuals with advanced non-small cell lung cancer (NSCLC) breathe easier and improve their daily lives. Participants will either undergo pulmonary rehabilitation for eight weeks or continue with their usual care. The trial includes interviews to identify any challenges participants or doctors encounter with this treatment. Individuals with advanced NSCLC who sometimes experience shortness of breath might be suitable for this study. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important findings.
Do I have to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that pulmonary rehabilitation is safe for people with advanced stage non-small cell lung cancer?
Research shows that pulmonary rehabilitation (PR) is generally safe for people with lung cancer. Studies have found that this treatment can improve exercise capacity and ease breathing. For instance, one study discovered that PR reduced complications after lung surgery and lowered the risk of breathing problems.
Another study examined patients with non-small cell lung cancer and found that PR reduced breathlessness and improved mood. These findings suggest that PR is well-tolerated.
Overall, PR appears to be a safe option for managing symptoms related to lung cancer.12345Why are researchers excited about this trial?
Researchers are excited about pulmonary rehabilitation (PR) for lung cancer because it offers a fresh approach beyond the usual treatments like surgery, chemotherapy, and radiation. PR focuses on improving lung function and overall fitness through tailored exercise and education, which can enhance quality of life and potentially improve treatment outcomes. Unlike traditional treatments that directly target cancer cells, this method empowers patients to strengthen their bodies and manage symptoms more effectively. By addressing physical and emotional well-being, PR could become a valuable complement to the existing standard of care.
What evidence suggests that pulmonary rehabilitation might be an effective treatment for advanced stage NSCLC?
Research has shown that pulmonary rehabilitation, which participants in this trial may receive, benefits people with lung cancer. One study found it improves exercise ability and overall health, which is important for better treatment results. Another study discovered it reduces the risk of complications after lung surgery by 60%. It also boosts muscle strength and general physical fitness. These improvements can lead to less shortness of breath and better daily functioning for people with lung cancer.12467
Who Is on the Research Team?
Melinda Hsu, MD, MS
Principal Investigator
Case Comprehensive Cancer Center, University Hospitals
Are You a Good Fit for This Trial?
This trial is for people who have advanced stage non-small cell lung cancer (NSCLC) and experience shortness of breath. It's designed to see if pulmonary rehabilitation can improve their breathing, energy levels, and overall quality of life.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomized to receive either eight weeks of pulmonary rehabilitation or usual care
Follow-up
Participants are monitored for changes in functional capacity and quality of life
Qualitative Interviews
Interviews conducted to assess attitudes and barriers to pulmonary rehabilitation
What Are the Treatments Tested in This Trial?
Interventions
- Pulmonary Rehabilitation
Find a Clinic Near You
Who Is Running the Clinical Trial?
Case Comprehensive Cancer Center
Lead Sponsor
United States Department of Defense
Collaborator